Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian M Slomovitz

Showing results (101-110 of 108) with videos related to

Pageof 11
Sort By:
You have reached the last page of results.This site can display upto 108 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 16, 2024
Pembrolizumab or Placebo Plus Adjuvant Chemotherapy With or Without Radiotherapy for Newly Diagnosed, High-Risk Endometrial Cancer: Results in Mismatch Repair-Deficient TumorsBrian M Slomovitz, David Cibula, Weiguo Lv, et al.
JCO Precision Oncology|February 9, 2022
Phase II Study of Taselisib in <i>PIK3CA</i>-Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol IIan E Krop, Opeyemi A Jegede, Juneko E Grilley-Olson, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|May 21, 2026
Lenvatinib plus pembrolizumab in participants with advanced or recurrent endometrial cancer: Study 309/KEYNOTE-775 and ENGOT-en9/LEAP-001 post-(neo)adjuvant therapy outcomesChristian Marth, Domenica Lorusso, Mariusz Bidziński, et al.
Future Oncology (London, England)|July 11, 2024
A Plain Language Summary of "Dostarlimab for primary advanced or recurrent endometrial cancer"Mansoor R Mirza, Dana M Chase, Brian M Slomovitz, et al.
The New England Journal of Medicine|March 27, 2023
Dostarlimab for Primary Advanced or Recurrent Endometrial CancerMansoor R Mirza, Dana M Chase, Brian M Slomovitz, et al.
Therapeutic Advances in Medical Oncology|October 14, 2025
A plain language summary publication of patients' survival with endometrial cancer treated with dostarlimab plus carboplatin-paclitaxelMatthew A Powell, Line Bjørge, Lyndsay Willmott, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|July 31, 2025
Uterine leiomyosarcomaGiorgio Bogani, Giuseppe Caruso, Isabelle Ray-Coquard, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 12, 2025
Phase II Trial of Ribociclib Plus Letrozole in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary, Fallopian Tube, or Peritoneum: A GOG Partners Trial (GOG 3026)Brian M Slomovitz, S John Weroha, Wei Deng, et al.
Pageof 11

Showing results (101-110 of 108) with videos related to

Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 108 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 16, 2024
Pembrolizumab or Placebo Plus Adjuvant Chemotherapy With or Without Radiotherapy for Newly Diagnosed, High-Risk Endometrial Cancer: Results in Mismatch Repair-Deficient TumorsBrian M Slomovitz, David Cibula, Weiguo Lv, et al.
JCO Precision Oncology|February 9, 2022
Phase II Study of Taselisib in <i>PIK3CA</i>-Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol IIan E Krop, Opeyemi A Jegede, Juneko E Grilley-Olson, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|May 21, 2026
Lenvatinib plus pembrolizumab in participants with advanced or recurrent endometrial cancer: Study 309/KEYNOTE-775 and ENGOT-en9/LEAP-001 post-(neo)adjuvant therapy outcomesChristian Marth, Domenica Lorusso, Mariusz Bidziński, et al.
Future Oncology (London, England)|July 11, 2024
A Plain Language Summary of "Dostarlimab for primary advanced or recurrent endometrial cancer"Mansoor R Mirza, Dana M Chase, Brian M Slomovitz, et al.
The New England Journal of Medicine|March 27, 2023
Dostarlimab for Primary Advanced or Recurrent Endometrial CancerMansoor R Mirza, Dana M Chase, Brian M Slomovitz, et al.
Therapeutic Advances in Medical Oncology|October 14, 2025
A plain language summary publication of patients' survival with endometrial cancer treated with dostarlimab plus carboplatin-paclitaxelMatthew A Powell, Line Bjørge, Lyndsay Willmott, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|July 31, 2025
Uterine leiomyosarcomaGiorgio Bogani, Giuseppe Caruso, Isabelle Ray-Coquard, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 12, 2025
Phase II Trial of Ribociclib Plus Letrozole in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary, Fallopian Tube, or Peritoneum: A GOG Partners Trial (GOG 3026)Brian M Slomovitz, S John Weroha, Wei Deng, et al.
Pageof 11